NCT01425879: MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery |
|
|
| Completed | 2 | 8 | US | Akt Inhibitor MK2206, MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study | National Cancer Institute (NCI) | Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IV Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma | 05/13 | 05/14 | | |
NCT01859182: Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery |
|
|
| Withdrawn | 2 | 0 | US | selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis, pharmacogenomic studies, quality-of-life assessment | National Cancer Institute (NCI) | Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Localized Unresectable Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Stage II Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer | 05/13 | 05/13 | | |
